Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IBI3005 in Advanced Solid Tumors
NCT06418061Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI3005 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Innovent Biologics. Primary endpoints: Numbers of subjects with adverse events up to 3 years, Number of subjects with clinically significant changes in physical examination results up to 3 years and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
IBI3005
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT06418061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418061.